Neurofibromatosis type 1 (NF1) is a rare, complex, and often under-recognized condition that presents significant diagnostic and management challenges, particularly for oncology nurses who play a central role in longitudinal patient care. Despite recent advances, including…
Management of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) has evolved rapidly and now includes indications across age groups. NF1 remains a complex, lifelong condition with diverse and evolving manifestations, requiring clinicians to maintain up-to-date knowledge of…
Management of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) has evolved rapidly and now includes indications across age groups. NF1 remains a complex, lifelong condition with diverse and evolving manifestations, requiring clinicians to maintain up-to-date knowledge of…
Despite significant advances in the management of advanced or recurrent endometrial cancer (EC)—including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies—delivering timely, guideline-compliant care remains complex. Rapidly evolving clinical evidence, the growing role…
Antibody-drug conjugates (ADCs) are redefining precision oncology by delivering potent therapies directly to tumor cells through highly specific molecular targeting. This innovative approach is rapidly becoming a cornerstone of cancer care, particularly in metastatic non-small cell…
Metastatic non-small cell lung cancer (mNSCLC) remains a leading cause of cancer mortality despite advances with targeted therapy and immune checkpoint inhibitors (ICIs). While PD-1/PD-L1 blockade has improved outcomes, most patients ultimately progress, and durable responses…
Despite advancements in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), resistance and recurrence occur frequently and mutations might develop during treatment. Given the diverse range of treatment side effects,…
Driven by new insights into tumor biology and immune response, the therapeutic landscape for advanced renal cell carcinoma (RCC) continues to rapidly expand. As immunotherapy and VEGF-targeted combinations become central to RCC management, oncology teams must…
Neuroendocrine prostate cancer (NEPC) and other aggressive histologic variants of prostate cancer (PC) represent rare but clinically devastating disease phenotypes. These tumors progress rapidly and often evade detection through conventional measures such as PSA monitoring and…
Von Hippel-Lindau (VHL) disease is associated with a range of tumor types that require timely recognition and coordinated management. Accurate diagnosis depends on careful evaluation of clinical presentation, imaging findings, and genetic assessment, as these insights…